x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma"s top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

science life sciences

All Episodes

00:22:24

Where Do We Go From Here? The Future of Women's Health

BioSpace ·

2024/04/25

The potential impacts on clinical trial outcomes warrant a discussion surrounding the current definition of women’s health. In the second episode on our series on women's health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories. Additionally, we discuss how broadening the definition will open funding to address women’s health. Host ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of

en

00:17:55

Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player

BioSpace ·

2024/04/24

Sanofi will cut an undisclosed number of jobs as it revamps its U.S. vaccines commercial operations, as well as 99 employees from its Belgian sites—moves that are part of a full pipeline reprioritization. Meanwhile, the company got a win this week, with its investigational BTK inhibitor rilzabrutinib generating positive results in a Phase III study for adult patients with persistent or chronic immune thrombocytopenia. Sanofi will present its Q1 earnings tomorrow. Meanwhile, the FDA announced an

en

00:20:06

Amylyx and ALS, Continued ADC Excitement, Dire Drug...

BioSpace ·

2024/04/17

The past two weeks have seen Amylyx lose its only marketed product but receive numerous accolades for its decision to voluntarily withdraw Relyvrio after a failed Phase III trial in amyotrophic lateral sclerosis. Analysts and insiders spoke with BioSpace this week about the company's future and a possible regulatory precedent for other drugs approved based on a single trial.Elsewhere, antibody-drug conjugates continue to steal the show in oncology. At the American Association for Cancer

en

00:19:30

It's a Design Problem: Women and Clinical Trials

BioSpace ·

2024/04/11

Last month, President Biden signed an Executive Order on Advancing Women’s Health Research and Innovation, signalling the significance of women's health to the government and consequently investors. While women’s clinical trial participation has increased, clinical trials still largely are not designed for women. In this episode, our guests discuss the many areas where trials can be improved, such as human and historical diagnosis and screening biases, accessibility, data capturing, and more

en

00:16:44

Alphabet Soup: AACR and ACC Dominate Headlines This Week

BioSpace ·

2024/04/10

Conference season is in full swing, with the American Association for Cancer Research and American College of Cardiology concurrently holding their annual meetings in San Diego and Atlanta, respectively. From opposite coasts, biopharma companies are presenting their latest data in the cancer and cardiology spaces, both hits and misses alike. Oncology continues to be a hot area for investment, with several highly anticipated readouts coming down the pike. In addition to all the data coming out of

en

00:11:58

Did WuXi Make a Whoopsie? US-China R&D Relations in...

BioSpace ·

2024/04/03

WuXi AppTec was once again in the news this week, with speculation that the China-based biotech allegedly handed a U.S. client’s intellectual property over to the Chinese government without consent. Meanwhile, Lonza’s $1.2 billion buy of a Roche biologics plant in California—one of the world’s largest biologics manufacturing facilities by volume—bodes well for the CDMO market, and BMS pulls ahead of Amgen in the race to bring a fully approved KRAS inhibitor to market for patients with certain types

en

00:22:14

Will the IRA’s Focus on the Pharmaceutical Industry...

BioSpace ·

2024/03/28

The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United State. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patient. Challenging as these issues are, they must be addressed to lower patient costs. In this episode, our guests discuss

en

00:16:48

Bayer’s sweeping executive cuts, Wegovy’s expanding...

BioSpace ·

2024/03/27

It was another busy week! Bayer reduced its executive suite from 14 to 8 as part of a major restructuring. Meanwhile, the government announced it will pay for Wegovy for patients with heart disease after the Novo Nordisk therapy was approved earlier this month for the cardiovascular indication. Plus, Mirador’s emergence from stealth and the FDA’s approval of the third therapy for Duchenne muscular dystrophy in less than a year.

en

00:15:11

Money talk: Salary trends and raises

BioSpace ·

2024/03/21

This week, we're talking money! Following the release of BioSpace's 2024 Salary Report, we discuss salary trends and how they are impacting the biopharma workforce. Considering growth rates, we also discuss asking for raises vs looking for a new job and what salary trends may spell out for the rest of the year. Guest Chantal Dresner, VP of Marketing, BioSpace Angela Gabriel, Content Manager - Careers, BioSpace Host ⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

en

00:17:45

Historic approval for MASH, CAR-Ts in the spotlight

BioSpace ·

2024/03/20

Phew, what a week! One of the most anticipated FDA decisions of the year dropped last week when the regulator approved Madrigal’s Rezdiffra as the first therapy for MASH (formerly known as NASH). Then on Friday, BioSpace kept a close eye on an advisory committee discussing J&J’s Carvykti and BMS’s Abecma, two CAR-T therapies seeking label expansions as earlier lines of treatment in multiple myeloma despite the risk of early death. Also discussed: BIO’s decision from last week to cut ties with

en

00:24:55

The unintended consequences of small molecules

BioSpace ·

2024/03/14

Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients. Topics explored in this discussion are potential reasons behind the small molecule negotiation timeline decision, the antibody drug conjugates (ADC) boom, the investment environment, and positive steps the government is making through legislation

en

00:15:37

The skinny on weight loss, donanemab and the State of...

BioSpace ·

2024/03/13

The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expansion. Also discussed: biosimilar approvals for Fresenius Kabi, and Sandoz. More news at the forefront of Alzheimer's treatment: Eli Lilly's donanemab decision date got pushed and now the FDA wants to discuss the drug’s safety and efficacy at an upcoming adcomm. And finally, politics: President Biden's State of the Union address ruffles

en

00:11:06

The ABCs of ADCs: Why antibody-drug conjugates are so...

BioSpace ·

2024/03/06

These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.

en

00:20:06

The gap is where the pain is: Drug pricing and...

BioSpace ·

2024/02/29

When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different parts of the industry come together to discuss the complexities surrounding drug spend and pricing, innovation, funding, and the overall healthcare system. This episode explores the drug pricing gap between consumer experience and industry norms. Join Lori and our KOLs as we explore the drivers of healthcare costs, the CBO, rebates, and overall spend

en

00:14:15

Sweet succession: Gonzalez, patent thickets and his...

BioSpace ·

2024/02/28

This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, and the future of biosimilars.Also discussed: Earlybird Health's $186m VC fund; and definitely not the IRA.

en

00:13:30

Iovance wins with Amtagvi and the ADC train chugs on

BioSpace ·

2024/02/21

This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.

en

00:29:06

Eyes on the prize: Novo buys Catalent

BioSpace ·

2024/02/14

This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regulators; as well as discussion around the ongoing issues with drug shortages and manufacturing challenges and whether it the move will help accelerate manufacturing for Wegovy and Ozempic. Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm? As mentioned in

en

00:20:36

Balancing act: Patient access and innovation

BioSpace ·

2024/02/07

This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What's the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotiations? Also discussed earnings including Novo Nordisk, who beat analyst expectations largely due to sales of Ozempic and Wegovy, AbbVie, Merck, and GSK.

en

00:17:40

Keep calm and CAR-T on?

BioSpace ·

2024/01/31

Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a probe into malignancies caused by CAR T therapies, and just last week the agency called for a class-wide box warning on all commercial CAR-T therapies with ongoing investigations into cases of secondary malignancies. How do we approach this balancing act of treatment and side effects? Also this week: IPOs march on with ArriVent, CG Oncology, Alto

en

00:18:18

What can biopharma expect from the job market?

BioSpace ·

2024/01/25

Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent Employment Outlook Report including unemployment, anticipated job search activity, hiring trends and current workforce sentiment.

en

221 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter